Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-14
1997-05-06
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514252, 514316, 544364, 544369, 544370, 546187, 546209, A61K 31445, C07D21148
Patent
active
056271972
ABSTRACT:
Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.
REFERENCES:
patent: 3856962 (1974-12-01), Alphin et al.
patent: 4970217 (1990-11-01), Pr ucher et al.
patent: 5053393 (1991-10-01), Tjoeng et al.
patent: 5256812 (1993-10-01), Alig et al.
patent: 5399585 (1995-03-01), Alig et al.
patent: 5532255 (1996-07-01), Raddatz et al.
Nierodzick, M. L. et al. Thrombosis and Haemostasis, 1995 (Jul), 74(1), pp. 282-290.
Valentin-Weigand et al., Infection and Immunity, 56(11):2851-2855 (Nov. 1988) Born, Nature, 194(4832):927-929 (Jun. 9, 1962).
Bernotat-Danielowski Sabine
Gante Joachim
Juraszyk Horst
Melzer Guido
Raddatz Peter
Dahlen Garth M.
Ivy C. Warren
Merck Patent Gesellschaft mit beschrankter Haftung
LandOfFree
Adhesion receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adhesion receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adhesion receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2132931